

**ASX ANNOUNCEMENT****28 April 2023****First Cann dried flower products cleared for sale in Germany**

**28 April 2023** –Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to advise that the Company's first shipment of dried flower to Germany has been successfully delivered and released for supply.

The product, a high THC flower, has been developed by Cann through an extensive internal R&D and breeding program and is part of the Company's strategic program to become a consistent supplier of high quality products to the overseas market.

Cann Group CEO Peter Koetsier said "Whilst our short-term priority remains supplying our Australian customers, this successful shipment signals the beginning of our plans in the coming months to increase sales overseas to countries such as Germany as our production capacity increases".

**Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.**

**For all information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO and Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market a proprietary delivery system for cannabinoids. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)